AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34225817 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of OnTrackNY program data
Number of subjects: 0
Study 34226183 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg twice daily
Number of subjects: 0
Study 34226183 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab
Number of subjects: 0
Study 34226183 — intervention group
Group type: COMPARATOR
Intervention: placebo-to-tofacitinib
Number of subjects: 0
Study 34226208 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/velpatasvir (SOF/VEL)
Number of subjects: 0
Study 34226208 — intervention group
Group type: COMPARATOR
Intervention: Control county (not specified)
Number of subjects: 0
Study 34226282 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic-euglycemic clamp
Number of subjects: 0
Study 34226282 — intervention group
Group type: COMPARATOR
Intervention: Control saline infusion (SC)
Number of subjects: 0
Study 34227124 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing starting at predicted maximum tolerated dose (MTD)
Number of subjects: 0
Study 34227407 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty of iliac and femoropopliteal arteries
Number of subjects: 411
Study 34227407 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty of iliac, femoral, and crural arteries
Number of subjects: 411
Study 34227407 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic angiography
Number of subjects: 411
Study 34227790 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (aerobic and resistance training) for 12 weeks, twice weekly
Number of subjects: 13
Study 34227790 — intervention group
Group type: COMPARATOR
Intervention: Baseline evaluation
Number of subjects: 13
Study 34227849 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral processes to clinic-community partnership programs for childhood obesity treatment
Number of subjects: 0
Study 34228090 — intervention group
Group type: EXPERIMENTAL
Intervention: RISE Model of resilience
Number of subjects: 36
Study 34228679 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-Day Surgery for Breast Cancer Patients
Number of subjects: 0
Study 34228679 — intervention group
Group type: COMPARATOR
Intervention: Standard Surgery Protocol
Number of subjects: 0
Study 34228983 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 0
Study 34228981 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-focus narrow-band imaging (NF-NBI)
Number of subjects: 100
Study 34228981 — intervention group
Group type: COMPARATOR
Intervention: NF white-light endoscopy (NF-WLE)
Number of subjects: 100
Study 34229125 — intervention group
Group type: COMPARATOR
Intervention: Lower arm blood pressure measurements
Number of subjects: 100
Study 34229125 — intervention group
Group type: COMPARATOR
Intervention: Wrist blood pressure measurements
Number of subjects: 100
Study 34229125 — intervention group
Group type: COMPARATOR
Intervention: Comparison of lower arm vs upper arm blood pressure measurements
Number of subjects: 100
Study 34229125 — intervention group
Group type: COMPARATOR
Intervention: Comparison of upper arm vs wrist blood pressure measurements
Number of subjects: 100
Study 34229186 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized antidepressant treatment protocol for 16 weeks
Number of subjects: 271
Study 34229268 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 200 mg PM
Number of subjects: 5
Study 34229268 — intervention group
Group type: EXPERIMENTAL
Intervention: Three daily dose of 67 mg PM
Number of subjects: 5
Study 34229268 — intervention group
Group type: COMPARATOR
Intervention: Control for dietary intake
Number of subjects: 5
Study 34229290 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization for acute exacerbations of COPD
Number of subjects: 1219
Study 34229290 — intervention group
Group type: COMPARATOR
Intervention: Outpatient exacerbations or no exacerbation
Number of subjects: 1219
Study 34229325 — intervention group
Group type: EXPERIMENTAL
Intervention: Return of results (RoR) structures embedded in clinical care
Number of subjects: 35
Study 34229325 — intervention group
Group type: EXPERIMENTAL
Intervention: Return of results (RoR) independent of clinical care
Number of subjects: 35
Study 34229325 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliance on clinical partnerships to facilitate RoR
Number of subjects: 35
Study 34229325 — intervention group
Group type: EXPERIMENTAL
Intervention: Accommodations for LRRP including social work referral and insurance enrollment assistance
Number of subjects: 35
Study 34229325 — intervention group
Group type: EXPERIMENTAL
Intervention: Support to access downstream treatment
Number of subjects: 35
Study 34229325 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of best practices and policies for managing RoR to LRRP
Number of subjects: 35
Study 34229330 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall TDR prevalence
Number of subjects: 573
Study 34229330 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonnucleoside reverse transcriptase inhibitor resistance
Number of subjects: 573
Study 34229330 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleoside reverse transcriptase inhibitor resistance
Number of subjects: 573
Study 34229330 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor resistance
Number of subjects: 573
Study 34229580 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP use
Number of subjects: 20
Study 34229705 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese version of the Pittsburgh Sleep Quality Index (PSQI)
Number of subjects: 402
Study 34229714 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 20
Study 34229714 — intervention group
Group type: COMPARATOR
Intervention: Healthy control-based translational approach
Number of subjects: 20
Study 34229929 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient screening mammography
Number of subjects: 101
Study 34230007 — intervention group
Group type: EXPERIMENTAL
Intervention: MDM2 inhibitor ALRN-6924
Number of subjects: 0
Study 34230007 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic activation of p53
Number of subjects: 0
Study 34230007 — intervention group
Group type: EXPERIMENTAL
Intervention: MDM2 inhibitors
Number of subjects: 0
Study 34230011 — intervention group
Group type: EXPERIMENTAL
Intervention: Butyrylcholinesterase (BChE) activity measurement preoperatively and postoperatively
Number of subjects: 48
Study 34230011 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative complication screening
Number of subjects: 48
Study 34230011 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care measurements for BChE
Number of subjects: 48
Study 34230013 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and geriatric and paraclinical parameters
Number of subjects: 0
Study 34230013 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional and nutritional parameters questionnaire
Number of subjects: 0
Study 34230013 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraclinical parameters at ICU admission
Number of subjects: 0
Study 34230013 — intervention group
Group type: EXPERIMENTAL
Intervention: Univariate and multivariate logistic regressions
Number of subjects: 0
Study 34230074 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging
Number of subjects: 0
Study 34231041 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention to improve fatigue
Number of subjects: 44
Study 34231041 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (no control group mentioned)
Number of subjects: 44
Study 34231126 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 240993
Study 34231126 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-β
Number of subjects: 240993
Study 34231126 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate
Number of subjects: 240993
Study 34231126 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 240993
Study 34231126 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 240993
Study 34231126 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate
Number of subjects: 240993
Study 34231126 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Number of subjects: 240993
Study 34231126 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Number of subjects: 240993
Study 34231126 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab, Interferon-β, Dimethyl fumarate
Number of subjects: 240993
Study 34231203 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological interventions (including psychoeducation, cognitive behavioural therapy, group discussion, peer education, and art therapy)
Number of subjects: 1357
Study 34231203 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological interventions
Number of subjects: 1357
Study 34231203 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1357
Study 34231374 — intervention group
Group type: EXPERIMENTAL
Intervention: Two different stretching techniques
Number of subjects: 0
Study 34231374 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 34231877 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-osteoporotic drugs (abaloparatide, alendronate, denosumab, raloxifene, teriparatide)
Number of subjects: 9164
Study 34231877 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-osteoporotic drugs
Number of subjects: 9164
Study 34231914 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid (morphine)
Number of subjects: 1110
Study 34231914 — intervention group
Group type: COMPARATOR
Intervention: Opioid (opioid vs clonidine)
Number of subjects: 1110
Study 34231914 — intervention group
Group type: COMPARATOR
Intervention: Opioid (opioid vs diazepam)
Number of subjects: 1110
Study 34231914 — intervention group
Group type: COMPARATOR
Intervention: Opioid (opioid vs phenobarbital)
Number of subjects: 1110
Study 34231914 — intervention group
Group type: COMPARATOR
Intervention: Opioid (morphine vs phenobarbital)
Number of subjects: 1110
Study 34231914 — intervention group
Group type: COMPARATOR
Intervention: Opioid (morphine vs chlorpromazine)
Number of subjects: 1110
Study 34232223 — intervention group
Group type: EXPERIMENTAL
Intervention: APO(a)LRx
Number of subjects: 0
Study 34232223 — intervention group
Group type: COMPARATOR
Intervention: Nicotinic acid
Number of subjects: 0
Study 34232223 — intervention group
Group type: COMPARATOR
Intervention: Proprotein convertase subtilisin/kexin 9 inhibitors
Number of subjects: 0
Study 34232223 — intervention group
Group type: COMPARATOR
Intervention: Antisense oligonucleotide
Number of subjects: 0
Study 34232291 — intervention group
Group type: EXPERIMENTAL
Intervention: Cer(d18:1/16:0)
Number of subjects: 920
Study 34232291 — intervention group
Group type: EXPERIMENTAL
Intervention: Cer(d18:1/22:0)
Number of subjects: 920
Study 34232291 — intervention group
Group type: EXPERIMENTAL
Intervention: Cer(d18:1/24:0)
Number of subjects: 920
Study 34232291 — intervention group
Group type: EXPERIMENTAL
Intervention: CERT-HBP (ceramide score)
Number of subjects: 920
Study 34232493 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized glycopyrrolate (GLY) 25 µg
Number of subjects: 22
Study 34232493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 34232578 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for postpartum depression
Number of subjects: 0
Study 34232694 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3-mSv CT
Number of subjects: 0
Study 34232694 — intervention group
Group type: COMPARATOR
Intervention: Standard-Dose CT
Number of subjects: 0
Study 34232841 — intervention group
Group type: EXPERIMENTAL
Intervention: Disc electrodes (DE)
Number of subjects: 29
Study 34232841 — intervention group
Group type: COMPARATOR
Intervention: Wire electrodes (WE)
Number of subjects: 29
Study 34233252 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers (n = 11,530)
Number of subjects: 50713
Study 34233252 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers (1 to 10 packs per year)
Number of subjects: 50713
Study 34233252 — intervention group
Group type: EXPERIMENTAL
Intervention: Older group (smokers)
Number of subjects: 50713
Study 34233252 — intervention group
Group type: EXPERIMENTAL
Intervention: Young middle age women (smokers)
Number of subjects: 50713
Study 34233252 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers (n = 39,183)
Number of subjects: 50713
Study 34233255 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 49
Study 34233255 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (SD)
Number of subjects: 49
Study 34233259 — intervention group
Group type: EXPERIMENTAL
Intervention: ALN-tumor radiomic signature for ALN status prediction
Number of subjects: 1088
Study 34233259 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiomic signature incorporating tumor and lymph node MRI radiomics, clinical and pathologic characteristics, and molecular subtypes
Number of subjects: 1088
Study 34233259 — intervention group
Group type: EXPERIMENTAL
Intervention: Key radiomic features before and after neoadjuvant chemotherapy
Number of subjects: 1088
Study 34233259 — intervention group
Group type: EXPERIMENTAL
Intervention: Association between MRI radiomics and tumor microenvironment features
Number of subjects: 1088
Study 34233458 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose derivative treatment
Number of subjects: 0
Study 34233538 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth PTC classes
Number of subjects: 114
Study 34233538 — intervention group
Group type: COMPARATOR
Intervention: In-person PTC classes
Number of subjects: 114
Study 34233836 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 4320
Study 34233836 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 4320
Study 34233836 — intervention group
Group type: COMPARATOR
Intervention: Gender (females vs males)
Number of subjects: 4320
Study 34233941 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic/Intermittent-Fasting Diet (GLAD)
Number of subjects: 25
Study 34233971 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple trapeziectomy
Number of subjects: 37329
Study 34233971 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroplasty
Number of subjects: 37329
Study 34233971 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrodesis
Number of subjects: 37329
Study 34233971 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall surgery
Number of subjects: 37329
Study 34233992 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment pathways for knee OA
Number of subjects: 0
Study 34233992 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient characteristics
Number of subjects: 0
Study 34233992 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive models
Number of subjects: 0
Study 34233992 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness evaluation
Number of subjects: 0
Study 34233992 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' perspectives
Number of subjects: 0
Study 34233996 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT-derived vulnerable plaque characteristics of nonflow limiting, nonculprit lesions
Number of subjects: 438
Study 34233999 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening positive for common mental disorders (CMD)
Number of subjects: 3480
Study 34233999 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting suicidal ideation
Number of subjects: 3480
Study 34233999 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting perceptual symptoms
Number of subjects: 3480
Study 34233999 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal adherence associated with positive CMD screen
Number of subjects: 3480
Study 34233999 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive CMD screens in women
Number of subjects: 3480
Study 34233999 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive CMD screens in adults aged 40-49 years
Number of subjects: 3480
Study 34233999 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive CMD screens in adults aged 50-59 years
Number of subjects: 3480
Study 34234010 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based high-flow nasal cannula (HFNC) protocol
Number of subjects: 0
Study 34234673 — intervention group
Group type: EXPERIMENTAL
Intervention: IMMH-010
Number of subjects: 0
Study 34234673 — intervention group
Group type: EXPERIMENTAL
Intervention: YPD-29B
Number of subjects: 0
Study 34234673 — intervention group
Group type: EXPERIMENTAL
Intervention: IMMH-010 and YPD-29B
Number of subjects: 0
Study 34235085 — intervention group
Group type: EXPERIMENTAL
Intervention: EphA2-redirected CAR T-cells (starting dosage 1×10)
Number of subjects: 3
Study 34235186 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant treatment
Number of subjects: 0
Study 34235186 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34235373 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace-based sugar-sweetened beverage (SSB) intervention over 10 months
Number of subjects: 212
Study 34235373 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace-based sugar-sweetened beverage (SSB) intervention
Number of subjects: 212
Study 34236245 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb hyperemia (verum group)
Number of subjects: 80
Study 34236245 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo group)
Number of subjects: 80
Study 34236298 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in opioid treatment as peer recovery support service interventionists
Number of subjects: 0
Study 34236338 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible endoscopic septotomy (FES)
Number of subjects: 256
Study 34236339 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk loci for anxiety and PTSD
Number of subjects: 28
Study 34236339 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety or PTSD genes
Number of subjects: 28
Study 34236339 — intervention group
Group type: EXPERIMENTAL
Intervention: CTNND2
Number of subjects: 28
Study 34236339 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicated systems
Number of subjects: 28
Study 34236339 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic predisposition to anxiety and PTSD
Number of subjects: 28
Study 34236401 — intervention group
Group type: EXPERIMENTAL
Intervention: PLX9486 at 500 mg or less
Number of subjects: 39
Study 34236401 — intervention group
Group type: EXPERIMENTAL
Intervention: PLX9486 at 1000 mg
Number of subjects: 39
Study 34236401 — intervention group
Group type: EXPERIMENTAL
Intervention: PLX9486 at 500 mg or less with sunitinib
Number of subjects: 39
Study 34236401 — intervention group
Group type: EXPERIMENTAL
Intervention: PLX9486 and sunitinib combination (25 or 37.5 mg)
Number of subjects: 39
Study 34236437 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall plant-based diet index (PDI)
Number of subjects: 74522
Study 34236437 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthful plant-based diet index (hPDI)
Number of subjects: 74522
Study 34236437 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhealthful plant-based diet index (uPDI)
Number of subjects: 74522
Study 34236525 — intervention group
Group type: COMPARATOR
Intervention: Lying position (LyP) for 30 minutes daily during the first 7 days of hospitalization
Number of subjects: 24
Study 34236570 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency intravascular ultrasound (RF-IVUS)
Number of subjects: 103
Study 34236570 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 103
Study 34236570 — intervention group
Group type: COMPARATOR
Intervention: Comparison of RF-IVUS and OCT
Number of subjects: 103
Study 34236570 — intervention group
Group type: COMPARATOR
Intervention: Reasons for discordance
Number of subjects: 103
Study 34236995 — intervention group
Group type: EXPERIMENTAL
Intervention: Pfizer-BioNTech COVID-19 vaccine (first dose)
Number of subjects: 19
Study 34236995 — intervention group
Group type: EXPERIMENTAL
Intervention: Pfizer-BioNTech COVID-19 vaccine (second dose)
Number of subjects: 19
Study 34236995 — intervention group
Group type: EXPERIMENTAL
Intervention: Pfizer-BioNTech COVID-19 vaccine (both doses)
Number of subjects: 19
Study 34237031 — intervention group
Group type: EXPERIMENTAL
Intervention: Larotrectinib
Number of subjects: 106
Study 34237031 — intervention group
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Number of subjects: 106
Study 34237031 — intervention group
Group type: EXPERIMENTAL
Intervention: Selpercatinib combined with 131I therapy
Number of subjects: 106
Study 34237031 — intervention group
Group type: EXPERIMENTAL
Intervention: Larotrectinib (in vitro)
Number of subjects: 106
Study 34237102 — intervention group
Group type: EXPERIMENTAL
Intervention: Skydiving
Number of subjects: 19
Study 34237102 — intervention group
Group type: COMPARATOR
Intervention: Control visit
Number of subjects: 19
Study 34237166 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiopoietin-2 (ANGPT2)
Number of subjects: 1853
Study 34237166 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiopoietin-like 4 protein (ANGPTL4)
Number of subjects: 1853
Study 34237347 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS) performed on days 3, 7, and 14 after birth
Number of subjects: 152
Study 34237347 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS) score >10 at all 3 time points
Number of subjects: 152
Study 34237347 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS)
Number of subjects: 152
Study 34237347 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS) alone
Number of subjects: 152
Study 34238024 — intervention group
Group type: EXPERIMENTAL
Intervention: Pericardial adipose tissue (PAT)
Number of subjects: 2882
Study 34238024 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral adipose tissue (VAT)
Number of subjects: 2882
Study 34238024 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous adipose tissue (SAT)
Number of subjects: 2882
Study 34238299 — intervention group
Group type: EXPERIMENTAL
Intervention: SD Biosensor Standard G6PD Test
Number of subjects: 45
Study 34238552 — intervention group
Group type: EXPERIMENTAL
Intervention: CTO PCI
Number of subjects: 0
Study 34238552 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0